TITLE

Managing Cancer-Related Anorexia/Cachexia

AUTHOR(S)
Mantovani, G.; Macciò, A.; Massa, E.; Madeddu, C.
PUB. DATE
February 2001
SOURCE
Drugs;Feb2001, Vol. 61 Issue 4, p499
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. This review examines the mechanisms of CAC and its management. All the potential modalities of intervention from nutritional to pharmacological approaches are included with a clear distinction between unproven, investigational and well established treatments. Among the latter, the progestogens are currently considered the most effective and safest drugs for the management of CAC. Agents currently under investigation for CAC include thalidomide, pentoxifylline and melatonin, which most probably act on cytokine release, and clenbuterol, which acts on muscle mass and to antagonise protein wasting. Our personal experience with the synthetic progestogens megestrol and medroxyprogesterone supports their use as first-line agents. In addition, our work on the potential role of antioxidant agents in counteracting the oxidative stress, which appears to be involved in CAC, shows them to be promising agents when used in combination chemotherapy regimens either alone or with other ‘biologics’. There is an ongoing need for quality of life questionnaires which specifically address the most significant symptoms present in patients with CAC.
ACCESSION #
4369355

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics